Breast cancer claims younger black female lives. If so, when should the screening begin?

Published Date: 26 Apr 2023

Once a woman turns 40, experts advise that she at the very least think about starting a breast cancer screening program. According to a recent study, Black women need this advice above all others.

Read Full News

Latest News

The Surprising Effects of Psychedelics on 'Normal' Adults

The first-ever dose of psilocybin produced in healthy volunteers “the single most unusual conscious state of their entire lives.”

Practice-Changing Ovarian Cancer Updates From SGO 2026

Dr Bradley Corr reviews data on the NRG-GY019 and ROSELLA trials, and discusses their clinical impact on ovarian cancer care.

Episode 5: Secondary Hypertension and Pregnancy

Drs Marwah Abdalla and Kara K. Hoppe discuss hypertension and pregnancy, including preconception counseling, postpartum management, and long-term cardiovascular health.

No Need to Worry About GLP-1-Induced Muscle Loss

Recent headlines have alarmingly stated dramatic muscle loss for patients on GLP-1s. Yoni Freedhoff, MD, explains why this is a manufactured controversy.

Woman Develops Systemic Sarcoidosis After Eyebrow Tattoo

A 46-year-old woman developed disseminated sarcoidosis after an eyebrow tattoo, with lesions spreading to distant, nontattooed skin and bilateral hilar nodes.

AF Pulsed Field Ablation Disappoints in Setup for Success

The AVANT GUARD trial design stacked the odds in favor of PFA over antiarrhythmic drugs. Yet, the results are unconvincing to this electrophysiologist. Maybe not all PFA systems are created equal.

Todays Updates

Most NMIBC Recurrences Seen in BCG-Exposed Patients

A large real-world study examines outcomes and treatment patterns among patients with non-muscle-invasive bladder cancer treated with BCG.

Todays Updates

Most NMIBC Recurrences Seen in BCG-Exposed Patients

A large real-world study examines outcomes and treatment patterns among patients with non-muscle-invasive bladder cancer treated with BCG.

Latest News

The first-ever dose of psilocybin produced in healthy volunteers “the single most unusual conscious state of their entire lives.”

Dr Bradley Corr reviews data on the NRG-GY019 and ROSELLA trials, and discusses their clinical impact on ovarian cancer care.

Drs Marwah Abdalla and Kara K. Hoppe discuss hypertension and pregnancy, including preconception counseling, postpartum management, and long-term cardiovascular health.

Recent headlines have alarmingly stated dramatic muscle loss for patients on GLP-1s. Yoni Freedhoff, MD, explains why this is a manufactured controversy.

A 46-year-old woman developed disseminated sarcoidosis after an eyebrow tattoo, with lesions spreading to distant, nontattooed skin and bilateral hilar nodes.

The AVANT GUARD trial design stacked the odds in favor of PFA over antiarrhythmic drugs. Yet, the results are unconvincing to this electrophysiologist. Maybe not all PFA systems are created equal.

News All Time

Don’t Sign Yet: What’s in Your Physician Agreement?

Don’t rely on verbal promises. Healthcare attorney Ericka Adler explains what physicians must get in writing before signing a physician agreement.

BCR in Prostate Cancer: What It Means and What Comes Next

Biochemical recurrence is one of the most challenging scenarios in prostate cancer care. Dr David Einstein explores how clinicians interpret rising PSA levels and highlights management strategies.

Mandrola’s Top 4 Trials from ACC 2026

Trials on Impella in high-risk PCI, percutaneous left atrial appendage closure, CTO-PCI, and spironolactone in HFpEF are Mandrola’s most anticipated at the upcoming 2026 ACC meeting in New Orleans.

US FDA Extends Review Of Lantheus' Diagnostic Imaging Kit by Three Months

Lantheus Holdings said on Tuesday that the U.S. health regulator has extended its review of the ⁠company's diagnostic imaging kit by three months as it needs more time to...

Can AI Restore the Power of the Stethoscope?

New trials show AI can identify serious cardiac disease from heart sounds alone, yet technology only changes outcomes when clinicians trust it and use it consistently.

Erectile Dysfunction in Young Man Reveals Prolactinoma

A laboratory abnormality during the evaluation of erectile dysfunction in a young man leads clinicians to identify hyperprolactinemia and a pituitary tumor on MRI.

Incidentalomas and Anxiety in Whole-Body Screening

Dr Bishal Gyawali discusses the rising trend of whole-body scans for cancer screening and how they can cause more harm than good.

Enhancing Shared Decision-Making in Early Breast Cancer

Experts discuss communication approaches that enhance shared decision-making for patients with early breast cancer, spanning surgery, adjuvant therapy, and survivorship.

Bannwarth Syndrome in a Woman With Early Breast Cancer

The case emphasizes Bannwarth syndrome as a rare but treatable cause of neurologic deterioration in an older woman receiving surgical cancer care.

Can Large Language Models Simplify Radiology Reports?

A meta-analysis suggests that large language model-simplified radiology reports improve patient understanding and readability while preserving high accuracy and completeness.

NPH: What You Learned in Med School Is Wrong

Neurologists Indu Subramanian and Alfonso Fasano discuss normal pressure hydrocephalus and why some of the classic dogma about this condition is wrong.

Promoting Whole-Body Imaging: Not There Yet

Ethicist Art Caplan discusses marketing promotions for expensive whole-body imaging.

Medicine Will Turn Cellular Age Backward by 2050: Barzilai

Aging may not be permanent. Nir Barzilai explains how human cells reset to zero and why partial rejuvenation could be possible within decades.

The Time Burden of Cancer Treatment

Dr Kathy Miller discusses a recent study quantifying the hidden time burden of cancer care and its impact on clinic operations and patient experience.

Adding to the Toolbox: Thyroid Artery Embolization

Drs Kaniksha Desai and Juan Camacho discuss thyroid artery embolization.

ASCO GI: Updates in Pancreatic, Gastric, CRC

Dr Emil Lou highlights practice-changing updates from ASCO GI, including new immunotherapy, targeted therapy, and circulating tumor DNA advances across gastrointestinal cancers.